Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coramitug - Novo Nordisk

Next Previous
Drug Profile

Coramitug - Novo Nordisk

Alternative Names: NN-6019; NNC6019-0001; PRX-004

Latest Information Update: 05 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Neotope Biosciences
  • Developer Novo Nordisk
  • Class Cardiovascular therapies; Eye disorder therapies; Immunotherapies; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Protein aggregation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Transthyretin-related hereditary amyloidosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Transthyretin-related hereditary amyloidosis
  • No development reported Cardiovascular disorders

Most Recent Events

  • 27 Apr 2026 Coramitug receives Fast Track designation for Transthyretin-related hereditary amyloidosis [IV,Infusion] in USA
  • 02 Mar 2026 Novo Nordisk A/S initiates enrollment in a phase I trial for Transthyretin targeted amyloidosis in Netherlands (IV, Infusion) (CTIS2024-519372-22-00)
  • 08 Nov 2025 Adverse events and efficacy data from a phase II trial in transthyretin-related hereditary amyloidosis presented at the American Heart Association Scientific Sessions 2025 (AHA-2025)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top